Weizmannia coagulans BCF-01: a novel gastrogenic probiotic for Helicobacter pylori infection control
Open Access
- 9 February 2024
- journal article
- research article
- Published by Taylor & Francis in Gut Microbes
- Vol. 16 (1) , 2313770
Abstract
The widespread prevalence of Helicobacter pylori infection, particularly in China, contributes to the development of gastrointestinal diseases. Antibiotics have limitations, including adverse reactions and increased antibiotic resistance. Therefore, identification of novel gastrogenic probiotics capable of surviving the acidic gastric environment and effectively combating H. pylori infection has potential in restoring gastric microbiota homeostasis. Five novel strains of human gastrogenic Weizmannia coagulans (BCF-01-05) were isolated from healthy gastric mucosa and characterized using 16S rDNA identification. Acid resistance, H. pylori inhibition, and adherence to gastric epithelial cells were evaluated in in-vitro experiments and the molecular mechanism explored in in-vivo experiments. Among the gastric-derived W. coagulans strains, BCF-01 exhibited the strongest adhesion and H. pylori inhibition, warranting further in-vivo safety evaluation. Through 16S rRNA sequencing of a mouse model, BCF-01 was determined to significantly restore H. pylori-associated gastric dysbiosis and increase the abundance of potential probiotic bacteria. Furthermore, BCF-01 enhanced mucosal tight junction protein expression and inhibited the TLR4-NFκB-pyroptosis signaling pathway in macrophages, as demonstrated by qRT-PCR and western blotting.These findings highlight the potential of BCF-01 in the prevention and control of H. pylori infection. Specifically, treatment with BCF-01 effectively restored gastric microecology and improved H. pylori-mediated mucosal barrier destruction while reducing inflammation through inhibition of the TLR4-NFκB-pyroptosis signaling pathway in macrophages. BCF-01 is a promising alternative to traditional triple therapy for H. pylori infections, offering minimal side effects with high suitability for high-risk individuals.Keywords
Funding Information
- National Natural Science Foundation of China (32300085)
- the Clinical Research Project of Nanfang Hospital (2021CR008)
- Research and Development (2022B1111070006)
- Scientific Research Project of Administration of Traditional Chinese Medicine of Guangdong Province (20221269)
This publication has 41 references indexed in Scilit:
- Biosorption of lead (Pb2+) by the vegetative and decay cells and spores of Bacillus coagulans R11 isolated from lead mine soilChemosphere, 2018
- Prevalence of Antibiotic Resistance in Helicobacter pylori: A Systematic Review and Meta-analysis in World Health Organization RegionsGastroenterology, 2018
- Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?American Journal of Gastroenterology, 2018
- Efficacy of Bacillus coagulans Unique IS2 in treatment of irritable bowel syndrome in children: a double blind, randomised placebo controlled studyBeneficial Microbes, 2018
- Effects of anti-Helicobacter pylori concomitant therapy and probiotic supplementation on the throat and gut microbiota in humansMicrobial Pathogenesis, 2017
- Probiotics as an adjuvant treatment in Helicobacter pylori eradication therapyJournal of Digestive Diseases, 2017
- The Toronto Consensus for the Treatment of Helicobacter pylori Infection in AdultsGastroenterology, 2016
- Evaluation of genetic and phenotypic consistency of Bacillus coagulans MTCC 5856: a commercial probiotic strainWorld Journal of Microbiology and Biotechnology, 2016
- Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot StudyProbiotics and Antimicrobial Proteins, 2014
- UPARSE: highly accurate OTU sequences from microbial amplicon readsNature Methods, 2013